Liprolog

Insulin Lispro, the active ingredient in Liprolog, is a short‑acting insulin presented as a solution for subcutaneous injection use. It is used to lower blood glucose in patients with diabetes mellitus and to manage acute hyperglycaemic emergencies. GNH USA supplies Liprolog as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Liprolog, a rapid‑acting insulin, is employed in the management of several diabetic conditions and related emergencies. - Type 1 diabetes mellitus: provides prompt post‑prandial glucose control. - Type 2 diabetes mellitus: assists in achieving target glycaemic levels when oral agents are insufficient. - Diabetic ketoacidosis: supplies immediate insulin activity to reduce ketone production. - Hyperglycemia: rapidly lowers elevated blood glucose during acute spikes.

Insulin Lispro may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Hypoglycaemia: low blood sugar episodes, especially if meals are missed. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase due to improved glucose utilization. - Lipodystrophy: localized changes in subcutaneous fat. - Nausea or mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hypoglycaemia: neuroglycopenic symptoms requiring immediate assistance. - Allergic reactions: urticaria, angio‑edema, or anaphylaxis. - Hypokalemia: low potassium levels, particularly with high insulin doses. - Acute insulin resistance: unexpected poor glucose response. - Serum insulin antibodies: may alter drug efficacy.

When prescribing Liprolog, clinicians should consider several safety measures. - Dose adjustment: tailor insulin dose based on frequent blood glucose monitoring and individual response. - Renal impairment: monitor closely as reduced clearance may increase hypoglycaemia risk. - Pregnancy: use only if benefits outweigh potential risks; data are limited. - Alcohol consumption: may potentiate insulin’s glucose‑lowering effect, increasing hypoglycaemia risk. - Hypoglycaemia unawareness: educate patients on recognizing subtle symptoms. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the product.

Insulin Lispro can interact with various medications, affecting glucose control.

Major Interactions (Avoid): - Beta‑blockers: may mask hypoglycaemia symptoms, delaying recognition. - Monoamine oxidase inhibitors (MAOIs): can increase the risk of severe hypoglycaemia. - Concurrent rapid‑acting insulins: additive glucose‑lowering effect may cause profound hypoglycaemia.

Moderate Interactions (Monitor Closely): - Sulfonylureas or other oral hypoglycaemics: may enhance insulin’s effect, requiring dose adjustments. - Thiazide diuretics: can raise blood glucose, potentially reducing insulin efficacy. - ACE inhibitors: may potentiate insulin’s glucose‑lowering action, necessitating monitoring.